[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2011071314A2 - Procédés de préparation de formes cristallines a et b d'ilaprazole et procédé de conversion des formes cristallines - Google Patents

Procédés de préparation de formes cristallines a et b d'ilaprazole et procédé de conversion des formes cristallines Download PDF

Info

Publication number
WO2011071314A2
WO2011071314A2 PCT/KR2010/008767 KR2010008767W WO2011071314A2 WO 2011071314 A2 WO2011071314 A2 WO 2011071314A2 KR 2010008767 W KR2010008767 W KR 2010008767W WO 2011071314 A2 WO2011071314 A2 WO 2011071314A2
Authority
WO
WIPO (PCT)
Prior art keywords
ilaprazole
acid
crystalline form
reaction solvent
preparing
Prior art date
Application number
PCT/KR2010/008767
Other languages
English (en)
Other versions
WO2011071314A3 (fr
Inventor
Dong Yeon Kim
Jae Soo Shin
Jun Yeoun Lee
Kwi Hyung Cho
Sung Tae Park
Jung Woo Kim
Sang Don Nam
Hee Yun Kim
Original Assignee
Il-Yang Pharm. Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Il-Yang Pharm. Co., Ltd. filed Critical Il-Yang Pharm. Co., Ltd.
Priority to UAA201207006A priority Critical patent/UA102787C2/ru
Priority to BR112012012212A priority patent/BR112012012212A2/pt
Priority to EA201200716A priority patent/EA019058B1/ru
Priority to IN3176DEN2012 priority patent/IN2012DN03176A/en
Publication of WO2011071314A2 publication Critical patent/WO2011071314A2/fr
Publication of WO2011071314A3 publication Critical patent/WO2011071314A3/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Definitions

  • the present invention relates to novel processes for preparing crystalline forms A and B of ilaprazole and the conversion of these crystalline forms.
  • Gastric and duodenal ulcers are a gastrointestinal disease caused by various factors such as mental stress, dietary habits, intake of irritable food, and the like.
  • the direct cause of peptic ulcers is damage to the gastric membrane due to excessive secretion of gastric acid.
  • therapeutic agents which have been commonly used for treatment of the peptic ulcers include, for example, antacids for neutralizing gastric acid, anti-pepsin agents, agents for protecting the gastric mucous membrane, anti-cholinergic agents for inhibiting gastric secretion, para-sympatholytic agents, H 2 -receptor antagonists, and the like.
  • H 2 -receptor antagonists as agents for treating gastric and duodenal ulcers has increased.
  • PPI formulations such as omeprazole have demonstrated excellent anticancer effects compared to existing H 2 receptor antagonists, including cimetidine, famotidine and ranitidine, and thus various PPI formulations have been developed and widely used.
  • the present inventors conducted studies for a long timeto develop a novel PPI compound and, as a result, invented ilaprazole, a compound having reduced side effects and high therapeutic effects compared to existing PPI compounds.
  • the invented ilaprazole was patented in many countries, including Korea (Korean Patent Application No. 10-1994-3833).
  • the following reaction scheme 1 shows a general process for preparing ilaprazole.
  • the physical or chemical properties of a drug can vary depending on the crystalline form of the drug, and such physical and chemical properties can greatly influence a suitable dosage form of the drug, the optimization of a process for preparing the drug, and the in vivo absorption of the drug.
  • the discovery of the most appropriate crystalline form of a drug in a procedure for developing the drug enables the development time and cost to be reduced.
  • International Patent Publication No. WO 2008/083333 discloses polymorphic forms of racemic ilaprazole and processes for preparing the same. According to the disclosure of WO 2008/083333, the crystalline form A of racemic ilaprazole is the most thermodynamically stable of these crystalline forms.
  • the crystalline form A is not easily dissolved in organic solvents containing water, but it is the most bio-available form, and thus is the most appropriate dosage form.
  • the crystalline form B of racemic ilaprazole can crystallize in pure form from aprotic solvents such as acetone/TEA, and thus has an advantage in that it can be purified during the preparation process.
  • the XRPD diffraction patterns of the crystalline forms A and B of racemic ilaprazole disclosed in International Patent Publication No. WO 2008/083333 are shown in Tables 1 and 2 below.
  • the DSC onset temperature of the crystalline form A of ilaprazole is 167 °C (max 170 °C)
  • the DSC onset temperature of the crystalline form of ilaprazole is 159 °C (max 163 °C).
  • the following reaction schemes 2 and 3 show processes for preparing crystalline forms A and B of ilaprazole, disclosed in International Patent Publication No. 2008/083333.
  • the process for preparing the crystalline form A of ilaprazole according to reaction scheme 2 above has the following shortcomings: 1) large amounts of various solvents are used in crystallization; 2) the preparation process is complex, because a concentration process should be carried out several times; 3) it is difficult to obtain the pharmaceutically required purity; and 4) a complex crystallization process is used, thus making it difficult to obtain the pure crystalline form A of ilaprazole.
  • the yield of the crystalline form A can be reduced when a process for increasing the purity is carried out, and also in that, because the amount of solvent used is large, the preparation process is not economical and can adversely affect the health of workers.
  • the process for preparing the crystalline form B of ilaprazole according to reaction scheme 3 above has the following shortcomings: 1) because the preparation process is a process of treating the already prepared crystalline form A, a process of preparing the crystalline form B is required; 2) the preparation process is time-consuming, because the crystallization process for obtaining the crystalline form B is continuously carried out for 11 days; and 3) the preparation process is not economical, because the use of an additional solvent is required in order to further treat the already prepared crystalline form A and because the additional process for treating the crystalline form A is carried out to reduce the yield of the crystalline form B. In addition, the preparation process is not suitable for mass production, and thus in some cases, the uniform crystalline form B is not obtained and the partially crystalline or non-uniform crystalline form B is obtained.
  • the present invention has been made in order to more efficiently solve the above-described problems occurringin the prior art.
  • the present invention adopts an industrially simple process compared to existing processes, enables a large amount of the pure crystalline form A of ilaprazole to be reproducibly obtained, is suitable for mass production, and allows the uniform crystalline form B of ilaprazole to be reproducibly obtained.
  • the present invention provides processes for preparing crystalline forms A and B of ilaprazole of the following formula 1 and a process for converting the crystalline forms, which enable the compounds to be obtained with high purity at low production cost in a shortened reaction time and show a reduced number of reaction processes and a high yield:
  • the present invention provides processes for preparing crystalline forms A and B of ilaprazole of the following formula 1 and a process for converting the crystalline forms:
  • the process for preparing crystalline A of ilaprazole according to the present invention includes the steps of: 1) preparing an inorganic salt of ilaprazole or a hydrate thereof from ilaprazole in the presence of an inorganic base and a reaction solvent; and 2) neutralizing the produced inorganic salt of ilaprazole or the hydrate thereof with an acid in a reaction solvent to prepare the crystalline form A of ilaprazole.
  • the process for preparing the crystalline form A of ilaprazole A according to the present invention may additionally include, after step 1), a step of adding a heterogeneous inorganic salt to prepare a heterogeneous inorganic salt of ilaprazole or a hydrate thereof.
  • the inorganic base or inorganic salt that is used in the step of preparing the inorganic salt or inorganic salt hydrate of ilaprazole may include lithium, titanium, barium, zinc, sodium, potassium, calcium, magnesium and/or strontium.
  • it may include zinc, sodium, potassium, calcium, magnesium and/or strontium. More preferably, it may include sodium, potassium, calcium, magnesium and/or strontium.
  • reaction solvent that is used in the step of preparing the inorganic salt or inorganic salt hydrate of ilaprazole may be a lower (C 1 ⁇ C 6 ) alkanol and/or a polar solvent.
  • the reaction solvent that is used in step 1 may be at least one selected from the group consisting of methanol, ethanol, propanol, xylene, toluene, tetrahydrofuran, 1,2-dichloroethane, acetone, ether, dichloromethane, acetonitrile, dimethylsulfoxide, dimethylformamide, and mixtures thereof.
  • it may be at least one selected from the group consisting of methanol, ethanol, propanol, tetrahydrofuran, acetone, and mixtures thereof. More preferably, it may be methanol, ethanol and/or propanol.
  • step 1) of preparing the inorganic salt or inorganic salt hydrate of ilaprazole may be performed by stirring the mixture at a temperature of 0 to 150 °C preferably 0 to 80 °C and more preferably room temperature to 50 °C but the stirring temperature is not specifically limited. Also, the stirring may preferablybe carried out, but the stirring time is not specifically limited.
  • the acid that is used in step 2) of preparing the crystalline form A of ilaprazole by neutralization with the acid may be at least one selected from the group consisting of chloroacetic acid, benzoic acid, butyric acid, sulfuric acid, hydrochloric acid, phosphoric acid, nitric acid, perchloric acid, formic acid, acetic acid, propionic acid, succinic acid, salicylic acid, methanesulfonic acid, ethanesulfonic acid, hydroxyethanesulfonic acid, ethylenesulfonic acid, toluenesulfonic acid, naphthylsulfonic acid, sulfanilic acid, hydroxybenzenesulfonic acid and tartaric acid.
  • it may be at least one selected from the group consisting of chloroacetic acid, benzoic acid, butyric acid, sulfuric acid, hydrochloric acid, phosphoric acid, nitric acid, perchloric acid, formic acid and acetic acid. More preferably, it may be benzoic acid, formic acid and/or acetic acid.
  • the reaction solvent that is used in step 2) of preparing the crystalline form A of ilaprazole may be a lower (C 1 ⁇ C 6 ) alkanol and/or a polar solvent.
  • the reaction solvent that is used in step 2) may be at least one selected from the group consisting of methanol, ethanol, propanol, xylene, toluene, tetrahydrofuran, 1,2-dichloromethane, acetone, ether, dichloromethane, acetonitrile, dimethylsulfoxide, dimethylformamide, and mixtures thereof.
  • it may be at least one selected from the group consisting of methanol, ethanol, propanol, tetrahydrofuran, acetone, and mixtures thereof. More preferably, it may be methanol, ethanol and/or propanol.
  • step 2) of preparing the crystalline form A of ilaprazole may be performed by stirringthe mixture at a temperature of 0 to 150 °C, preferably 0 to 80 °C, and more preferably room temperature to 50 °C, but the stirring temperature is not specifically limited. Also, the stirring may preferably be carried out for 1-6 hours, but the stirring time is not specifically limited.
  • the process for preparing the crystalline form B of ilaprazole according to the present invention may include a step of preparing the crystalline form B of ilaprazole from ilaprazole in a reaction solvent.
  • the reaction solvent that is used in the step of preparing the crystalline form B of ilaprazole may be a lower (C 1 ⁇ C 6 ) alkanol and/or a polar solvent.
  • the reaction solvent that is used in this step may be at least one selected from the group consisting of tetrahydrofuran, 1,2-dichloroethane, methanol, ethanol, propanol, acetone, dichloromethane, diethylether, ethylacetate, and mixtures thereof. More preferably, it may be at least one selected from the group consisting of methanol, ethanol, acetone, dichloromethane, diethylether, ethylacetate, and mixtures thereof.
  • a stabilizing agent may be added to the reaction solvent.
  • a stabilizing agent that may be used in this step is not specifically limited, but it may be at least one selected from the group consistingof, for example, triethylamine, diethylamine, ethylenediamine, trimethylamine, diisopropylethylamine and pyridine.
  • the step of preparing the crystalline form B of ilaprazole may be performed by stirring the mixture at a temperature of 30 to 150 °C, preferably 0 to 150 °C, more preferably 0 to 80 °C, and even more preferably room temperature to 50 °C,but the stirring temperature is not specifically limited. Also, the stirring may preferably be carried out for 1-6 hours, but the stirring time is notspecifically limited.
  • the starting material ilaprazole may be non-crystallized ilaprazole such as crude ilaprazole.
  • the process for converting crystalline forms of ilaprazole according to the present invention may include a step of converting the crystalline form A into crystalline form B of ilaprazole or converting the crystalline form B into crystalline form A of ilaprazole.
  • a solvent that may be used when preparing the crystalline form B from ilaprazole may be used.
  • an inorganic salt, a reaction solvent and/or an acid which may be used when preparing the crystalline form A from ilaprazole, may be used.
  • FIG. 1 is the XRPD diffraction pattern of the crystalline form A of ilaprazole according to the present invention
  • FIG. 2 is the DSC thermogram of the crystalline form A of ilaprazole according to the present invention
  • FIG. 3 is the IR spectrum of the crystalline form A of ilaprazole according to the present invention.
  • FIG. 4 is the 1 H-NMR spectrum of the crystalline form A of ilaprazole according to the present invention.
  • FIG. 5 is the XRPD diffraction pattern of the crystalline form B of ilaprazole according to the present invention.
  • FIG. 6 is the DSC thermogram of the crystalline form B of ilaprazole according to the present invention.
  • FIG. 7 is the IR spectrum of the crystalline form B of ilaprazole according to the present invention.
  • FIG. 8 is the 1 H-NMR spectrum of the crystalline form B of ilaprazole according to the present invention.
  • Ilaprazole sodium salt (12.87 mole, 5.0 kg) was added to 100 L of ethanol and neutralized by slow addition of a 10% (w/w) ethanol solution of acetic acid. Then, the mixture was stirred at room temperature for 2 hours. The produced solid was filtered, washed with 20 L of a 50% (v/v) ethanol aqueous solution, and then dried at 40 °Cfor 12 hours, thereby obtaining 4.06 kg (86% yield) of the pure title compound as white crystalline powder.
  • the results of analysis of the obtained powder are as follows.
  • Ilaprazole sodium salt (25.7 mmole, 10.0 g) was added to 200 ml of ethanol and neutralized by slow addition of a 10% (w/w) ethanol solution of benzoic acid. Then, the mixture was stirred at room temperature for 2 hours. The produced solid was filtered, washed with 40 ml of a 50% (v/v) ethanol aqueous solution, and then dried at 40 °Cfor 12 hours, thereby obtaining 7.7 g (82% yield) of the pure title compound as white crystalline powder.
  • Ilaprazole sodium salt (25.7 mmole, 10.0 g) was added to 200 ml of ethanol and neutralized by slow addition of a 10% (w/w) ethanol solution of formic acid. Then, the mixture was stirred at room temperature for 2 hours. The produced solid was filtered, washed with 40 ml of a 50% (v/v) ethanol aqueous solution, and then dried at 40 °Cfor 12 hours, thereby obtaining 8.1 g (86% yield) of the pure title compound as white crystalline powder.
  • Ilaprazole potassium salt (24.7 mmole, 10.0 g) was added to 200 ml of ethanol and neutralized by slow addition of a 10% (w/w) ethanol solution of acetic acid. Then, the mixture was stirred at room temperature for 2 hours. The produced solid was filtered, washed with 40 ml of a 50% (v/v) ethanol aqueous solution, and then dried at 40 °C for 12 hours, thereby obtaining 7.4 g (82% yield) of the pure title compound as white crystalline powder.
  • Ilaprazole calcium salt trihydrate (12.1 mmole, 10.0 g) was added to 200 ml of ethanol and neutralized by slow addition of a 10% (w/w) ethanol solution of acetic acid. Then, the mixture was stirred at room temperature for 2 hours.Then, the produced solid was filtered, washed with 40 ml of a 50% (v/v) ethanol aqueous solution, and then dried at 40 °C for 12 hours, thereby obtaining 7.5 g (84% yield) of the pure title compound as white crystalline powder.
  • Ilaprazole potassium salt (24.7 mmole, 10.0 g) was dissolved in 20 ml of water, and magnesium chloride (49.4 mmole, 4.7 g)was added thereto. Then, the mixture was stirred at room temperature for 4 hours. The produced solid was filtered, washed with 25 ml of methanol, and then dried at 40 °C for 12 hours, thereby obtaining 8.7 g (89% yield) of the pure title compound as white crystalline powder.
  • Ilaprazole potassium salt (24.7 mmole, 10.0 g) was dissolved in 20 ml of water, and magnesium chloride (49.4 mmole, 4.7 g)was added thereto. Then, the mixture was stirred at room temperature for 4 hours. The produced solid was filtered, added to 75 ml of water and stirred at room temperature for 6 hours. The resulting solid was filtered, washed with 25 ml of methanol, and then dried at 40 °C for 12 hours, thereby obtaining 7.5 g (75% yield) of the pure title compound as white crystalline powder.
  • Ilaprazole sodium salt (25.7 mmole, 10.0 g) was dissolved in 130 ml of water, and a solution of magnesium chloride (12.9 mmole, 1.2 g)in 48 ml of water was added thereto. Then, the mixture was stirred at room temperature for 1 hour. The produced solid was filtered, washed with 30 ml of water, and then dried at 40 °Cfor 12 hours, thereby obtaining 9.8 g (92% yield) of the pure title compound as white crystalline powder.
  • Ilaprazole magnesium salt tetrahydrate (12.1 mmole, 10.0 g) was added to 200 ml of ethanol and neutralized by slow addition of a 10% (w/w) ethanol solution of acetic acd. Then, the mixture was stirred at room temperature for 2 hours. The produced solid was filtered, washed with 40 ml of a 50% (v/v) ethanol aqueous solution, and then dried at 40 °C for 12 hours, thereby obtaining 7.4 g (83% yield) of the pure title compound as white crystalline powder.
  • Strontium chloride (hexahydrate) (30.9 mmole, 8.2 g) was dissolved in 120 mlof methanol, and a solution of ilaprazole sodium salt (51.5 mmole, 20.0 g) in 120 ml of water was added thereto. Then, the produced solid was filtered, washed with 120 ml of a mixed solvent of water and methanol, and then dried at 40 °C for 12hours, thereby obtaining 17.2 g (78% yield) of the pure title compound as white crystalline powder.
  • Ilaprazole strontium salt dehydrate (11.7 mmole, 10.0 g) was added to 200 ml of ethanol and neutralized by slow addition of a 10% (w/w) ethanol solution of acetic acid. Then, the mixture was stirred at room temperature for 2 hours. The produced solid was filtered, washed with 40 ml of a 50% (v/v) ethanol aqueous solution, and then dried at 40 °Cfor 12 hours, thereby obtaining 7.0 g (82% yield) of the pure title compound as white crystalline powder.
  • Ilaprazole (16.38 mole, 6.0 kg) was dissolved in 30 L of a mixed solvent of methanol and dichloromethane and added slowly to 150 L of diethylether. Then, the mixture was stirred at room temperature for 45 minutes. The producedsolid was filtered, washed with 3 L of diethylether, and then dried at 30 °C for 12 hours, thereby obtaining 5.1 kg (85% yield) of the pure title compound as white crystalline powder.
  • the results of analysis of the obtained powder are as follows.
  • Ilaprazole (54.6 mmole, 20.0 g) was dissolved in 260 ml of dichloromethane, and the solutionwas concentrated under reduced pressure to a volume of 80 ml.
  • the concentrated ethyl acetate solution was added slowly to 266 ml of ethyl acetate, and then stirred at a temperature between -10 °C and -15 °C for about 3-4 hours.
  • the produced solid was filtered, washed with 100 ml of diethylether, and then dried at 30 °C for 12 hours, thereby obtaining 17.8 g (89% yield) of the pure title compound as white crystalline powder.
  • Ilaprazol (27.3 mmole, 10.0 g) was dissolved in 130 ml of a mixed solvent of dichloromethane and triethylamine (1%, v/v), and 150 ml of acetone was added thereto. Then, the solution was concentrated under reduced pressure to a volume of 130 ml.130 ml of diethylether was added slowly to the concentrated solution, and the mixture was stirred at room temperature for 2 hours. The produced solid was filtered, washed with 100 ml of diethylether, and then dried at 30 °C for 12 hours, thereby obtaining 8.1 g (81% yield) of the pure title compound as white crystalline powder.
  • Ilaprazole (27.3 mmole, 10.0 g) was dissolved in 130 ml of a mixed solvent of dichloromethane and triethylamine (1%, v/v), and 130 ml of diethylether was slowly added thereto. Then, the mixture was stirred at room temperature for 2 hours. The produced solid was filtered, washed with 100 ml of diethylether, and then dried at 30 °C for 12 hours, thereby obtaining 7.6 g (76%yield) of the pure title compound as white crystalline powder.
  • Example 23 Conversion of crystalline form B of ilaprazole into crystalline form A of illaprazole
  • ilaprazole sodium salt (49.2 mmole, 19.1 g) was added to 380 mlof ethanol and neutralized by slow addition of a 10% (w/w) ethanol solution of acetic acid.
  • Example 24 Conversion of crystalline form A of ilaprazole into crystalline form B of ilaprazole
  • the crystalline form A of ilaprazole (54.6 mmole, 20.0 g) was dissolved in 100 ml of a mixed solvent of methanol and dichloromethane and added slowly to 500 ml of diethylether. Then, the mixture was stirred at room temperature for 45 minutes. The produced solid was filtered, washed with 200 ml of diethylether, and then dried at 30 °C for 12 hours, thereby obtaining 16.6 g (83% yield) of the pure title compound as white crystalline powder.
  • 0.5% ammonia water/ethanol (1.0 kg) was placed in the flask, and dichloromethane (2.4 kg) was added thereto. Then, the solution was concentrated under reduced pressure at a temperature of 20 to 25 °C to a volume of about 1.0 L. 0.5% ammonia water/ethanol (1.2 kg) was placed in the flask, and the solution was concentrated again under reduced pressure at a temperature of 20 to 25 °C to a volume of about 1.2 L. 0.5% ammonia water/ethanol (0.2 kg) was added to the concentrated solution, and the solution was cooled to about 5 °C and then stirred for 45 minutes.
  • the resulting slurry was filtered and washed with 0.5% ammonia water/ethanol (0.2 kg), ethanol (0.2 kg) and MTBE (2 x 0.2 kg).
  • the filtered solid was dried for 2 hours and vacuum-dried at a temperature of 92 °C or below for 92 hours, thereby obtaining 0.338 kg (85% yield) of the crystalline form A of ilaprazole.
  • the crystalline form A of ilaprazole was added to 10 ml of acetone/triethylamine and sonicated at room temperature for about 5 minutes to make a saturated solution of ilaprazole.
  • the slurry was filtered through a nylon filter into a glass vial.
  • the filtered slurry was allowed to stand in a refrigerator for 11 days and then filtered, thereby obtaining a white crystalline form B of ilaprazole.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne de nouveaux procédés pour la préparation des formes cristallines A et B d'ilaprazole de formule 1 et la conversion de ces formes cristallines. Les nouveaux procédés comprennent un procédé de préparation de la forme cristalline A d'une pureté élevée par la préparation d'un sel inorganique d'ilaprazole ou d'un hydrate de celui-ci, puis la neutralisation du sel inorganique d'ilaprazole préparé ou de l'hydrate de celui-ci par un acide dans un solvant organique (solvant unique ou solvant mixte), un procédé de préparation de la forme cristalline B de pureté élevée par l'élimination des impuretés de l'ilaprazole à l'aide d'un solvant organique (solvant unique ou solvant mixte) ; et un procédé de conversion de la forme cristalline A en la forme cristalline B ou de la forme cristalline B en la forme cristalline A.
PCT/KR2010/008767 2009-12-08 2010-12-08 Procédés de préparation de formes cristallines a et b d'ilaprazole et procédé de conversion des formes cristallines WO2011071314A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
UAA201207006A UA102787C2 (ru) 2009-12-08 2010-12-08 Способ приготовления кристаллических форм а и в илапразола и способ преобразования кристаллических форм
BR112012012212A BR112012012212A2 (pt) 2009-12-08 2010-12-08 processos de preparo de formas cristalinas a e b de ilaprazol e processo para conversão das formas cristalinas
EA201200716A EA019058B1 (ru) 2009-12-08 2010-12-08 Способ получения кристаллических форм а и в илапразола и способ превращения указанных кристаллических форм
IN3176DEN2012 IN2012DN03176A (fr) 2009-12-08 2010-12-08

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020090121209A KR101144600B1 (ko) 2009-12-08 2009-12-08 일라프라졸의 결정형 ａ, ｂ의 제조방법 및 이들 결정형의 변환방법
KR10-2009-0121209 2009-12-08

Publications (2)

Publication Number Publication Date
WO2011071314A2 true WO2011071314A2 (fr) 2011-06-16
WO2011071314A3 WO2011071314A3 (fr) 2011-11-10

Family

ID=44146052

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/008767 WO2011071314A2 (fr) 2009-12-08 2010-12-08 Procédés de préparation de formes cristallines a et b d'ilaprazole et procédé de conversion des formes cristallines

Country Status (7)

Country Link
KR (1) KR101144600B1 (fr)
BR (1) BR112012012212A2 (fr)
CO (1) CO6541539A2 (fr)
EA (1) EA019058B1 (fr)
IN (1) IN2012DN03176A (fr)
UA (1) UA102787C2 (fr)
WO (1) WO2011071314A2 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102746275A (zh) * 2012-06-21 2012-10-24 丽珠医药集团股份有限公司 结晶型艾普拉唑钠及其制备方法
CN102746276A (zh) * 2012-06-21 2012-10-24 丽珠医药集团股份有限公司 一种艾普拉唑钠晶型及其制备方法
CN102746277A (zh) * 2012-06-21 2012-10-24 丽珠医药集团股份有限公司 一种结晶形式的艾普拉唑钠及其制备方法
CN103204842A (zh) * 2012-01-13 2013-07-17 丽珠医药集团股份有限公司 结晶型艾普拉唑钠水合物及其制备方法
CN103204843A (zh) * 2012-01-13 2013-07-17 丽珠医药集团股份有限公司 结晶型艾普拉唑钠乙醇化物及其制备方法
WO2013114232A1 (fr) 2012-02-02 2013-08-08 Lupin Limited Procédé de préparation de forme cristalline l d'ilaprazole
CN105461692A (zh) * 2014-09-04 2016-04-06 江苏奥赛康药业股份有限公司 艾普拉唑钠化合物及其药物组合物
CN107857756A (zh) * 2017-11-06 2018-03-30 丽珠医药集团股份有限公司 一种艾普拉唑镁晶型及其制备方法
CN111187255A (zh) * 2020-01-13 2020-05-22 丽珠医药集团股份有限公司 右旋艾普拉唑钾盐的制备方法和右旋艾普拉唑的制备方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102027388B1 (ko) * 2017-11-15 2019-10-01 주식회사 다산제약 고순도 일라프라졸 결정형 b의 제조방법
KR20220065235A (ko) 2020-11-13 2022-05-20 주식회사 파마코스텍 일라프라졸 혼형 결정의 신규한 제조방법
KR102250509B1 (ko) * 2020-12-09 2021-05-11 유니셀랩 주식회사 새로운 일라프라졸/자일리톨 공결정
KR20210019469A (ko) 2021-02-02 2021-02-22 주식회사 파마코스텍 일라프라졸 나트륨 결정형 및 신규한 제조방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080200515A1 (en) * 2006-12-29 2008-08-21 Tap Pharmaceutical Products Inc. Solid state forms of enantiopure ilaprazole
KR20090086121A (ko) * 2006-12-29 2009-08-10 일양약품주식회사 용매화 일라프라졸의 결정형

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080200515A1 (en) * 2006-12-29 2008-08-21 Tap Pharmaceutical Products Inc. Solid state forms of enantiopure ilaprazole
KR20090086121A (ko) * 2006-12-29 2009-08-10 일양약품주식회사 용매화 일라프라졸의 결정형
KR20090086615A (ko) * 2006-12-29 2009-08-13 일양약품주식회사 라세믹 일라프라졸의 고체상 형태

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103204843B (zh) * 2012-01-13 2014-12-31 丽珠医药集团股份有限公司 结晶型艾普拉唑钠乙醇化物及其制备方法
CN103204843A (zh) * 2012-01-13 2013-07-17 丽珠医药集团股份有限公司 结晶型艾普拉唑钠乙醇化物及其制备方法
CN103204842A (zh) * 2012-01-13 2013-07-17 丽珠医药集团股份有限公司 结晶型艾普拉唑钠水合物及其制备方法
CN103204842B (zh) * 2012-01-13 2014-10-15 丽珠医药集团股份有限公司 结晶型艾普拉唑钠水合物及其制备方法
WO2013114232A1 (fr) 2012-02-02 2013-08-08 Lupin Limited Procédé de préparation de forme cristalline l d'ilaprazole
CN102746275B (zh) * 2012-06-21 2014-07-16 丽珠医药集团股份有限公司 结晶型艾普拉唑钠及其制备方法
CN102746276A (zh) * 2012-06-21 2012-10-24 丽珠医药集团股份有限公司 一种艾普拉唑钠晶型及其制备方法
CN102746275A (zh) * 2012-06-21 2012-10-24 丽珠医药集团股份有限公司 结晶型艾普拉唑钠及其制备方法
CN102746277A (zh) * 2012-06-21 2012-10-24 丽珠医药集团股份有限公司 一种结晶形式的艾普拉唑钠及其制备方法
CN105461692A (zh) * 2014-09-04 2016-04-06 江苏奥赛康药业股份有限公司 艾普拉唑钠化合物及其药物组合物
CN113045544A (zh) * 2014-09-04 2021-06-29 江苏奥赛康药业有限公司 艾普拉唑钠化合物及其药物组合物
CN107857756A (zh) * 2017-11-06 2018-03-30 丽珠医药集团股份有限公司 一种艾普拉唑镁晶型及其制备方法
CN115403560A (zh) * 2017-11-06 2022-11-29 丽珠医药集团股份有限公司 一种艾普拉唑镁晶型及其制备方法
CN115403560B (zh) * 2017-11-06 2024-09-03 丽珠医药集团股份有限公司 一种艾普拉唑镁晶型及其制备方法
CN111187255A (zh) * 2020-01-13 2020-05-22 丽珠医药集团股份有限公司 右旋艾普拉唑钾盐的制备方法和右旋艾普拉唑的制备方法
CN111187255B (zh) * 2020-01-13 2021-07-20 丽珠医药集团股份有限公司 右旋艾普拉唑钾盐的制备方法和右旋艾普拉唑的制备方法

Also Published As

Publication number Publication date
CO6541539A2 (es) 2012-10-16
KR101144600B1 (ko) 2012-05-16
EA019058B1 (ru) 2013-12-30
BR112012012212A2 (pt) 2015-09-08
KR20110064545A (ko) 2011-06-15
UA102787C2 (ru) 2013-08-12
WO2011071314A3 (fr) 2011-11-10
EA201200716A1 (ru) 2012-10-30
IN2012DN03176A (fr) 2015-09-25

Similar Documents

Publication Publication Date Title
WO2011071314A2 (fr) Procédés de préparation de formes cristallines a et b d'ilaprazole et procédé de conversion des formes cristallines
WO2016085221A2 (fr) Dérivé d'hétéroarylamine utilisable en tant qu'inhibiteur des protéines kinases
WO2014058268A1 (fr) Cristal monohydrate de sel de potassium de fimasartan, son procédé de préparation, et composition pharmaceutique le comprenant
WO2010030132A9 (fr) Procédé de purification d'adefovir dipivoxil
WO2013022243A2 (fr) Nouveau dérivé biphénylé ou sel pharmaceutiquement acceptable de celui-ci, et composition pharmaceutique pour prévenir ou traiter les maladies inflammatoires ou les maladies auto-immunes comprenant ce dérivé ou ce sel comme principe actif
WO2018194416A1 (fr) Nouveau composé solide cristallin de chlorhydrate de 3-phényl-4-propyl-1-(pyridin-2-yl)-1h-pyrazol-5-ol
WO2011004980A2 (fr) Procédé de préparation de dérivés tricycliques
EP2611776A2 (fr) Procédé de production d'un composé intermédiaire pour la synthèse d'un médicament
EP2560955A2 (fr) Nouveaux dérivés de benzamide
WO2010110622A2 (fr) Nouvelles formes cristallisées de l'adéfovir dipivoxil et leurs procédés de préparation
WO2012148246A2 (fr) Procédé de préparation de sitagliptine
WO2014010990A1 (fr) Nouveaux dérivés de pyridine et procédé de préparation d'un composé intermédiaire pour la fabrication d'herbicides de suflonylurée l'utilisant
EP3224257A1 (fr) Nouveau procédé de préparation d'un composé de thiénopyrimidine et intermédiaires utilisés dans ce procédé
WO2022220612A1 (fr) Procédé de préparation d'intermédiaire pour la synthèse d'un agoniste du récepteur de la sphingosine-1-phosphate
WO2015178663A1 (fr) Procédé amélioré de préparation de zabofloxacine
WO2020060213A1 (fr) Procédé de production d'un dérivé de 4-méthoxy pyrrole
WO2021029450A1 (fr) Nouveau dérivé de pyrimidine sulfonamide et composition pharmaceutique pour prévenir ou traiter le cancer le comprenant en tant que principe actif
WO2017090991A1 (fr) Procédé de purification de dérivé de benzopyrane, forme cristalline correspondante et procédé de préparation de la forme cristalline
WO2021045585A1 (fr) Procédé de production d'un composé de bipyridine pyrimidinyle et intermédiaire pour celui-ci
WO2024025393A1 (fr) Nouveau sel de composé imidazo[1,2-a]pyridine, forme cristalline de celui-ci et procédé de préparation
WO2023113458A1 (fr) Nouveau sel de dérivé de 1-sulfonyle pyrrole, son procédé de préparation et composition pharmaceutique le comprenant
WO2018038297A1 (fr) Nouveau sel de (r)- (1-méthylpyrrolidin-3-yl) méthyl (3'-chloro -4'-fluoro- [1,1'-biphényl]-2-yl) carbamate et forme cristalline de celui-ci
WO2023101115A1 (fr) Procédé de préparation d'un isomère unique de 1-(1-(2-benzylphénoxy)propan-2-yl)-2-méthylpipéridine de pureté élevée
WO2020009374A1 (fr) Nouveaux dérivés d'oxazoloquinolinone substitués en position 4, sel pharmaceutiquement acceptable de ceux-ci et composition pharmaceutique pour la prévention ou le traitement de maladies allergiques notamment l'asthme ou la dermatite atopique les comprenant
WO2012050380A2 (fr) Nouveaux dérivés de pyridyl-benzoxazine, composition pharmaceutique les contenant et leur utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10836209

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 3176/DELNP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 201200716

Country of ref document: EA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012001528

Country of ref document: CL

Ref document number: 1201002276

Country of ref document: TH

Ref document number: 12097489

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: A201207006

Country of ref document: UA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012012212

Country of ref document: BR

122 Ep: pct application non-entry in european phase

Ref document number: 10836209

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112012012212

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120522